Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Big Acquisition!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by kuatoliveson Oct 04, 2016 10:51am
87 Views
Post# 25306559

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Big Acquisition!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Big Acquisition!No, but an analyst asked if this drug would be responsible for company profitibility in 2017 and asked what the margins were. The CFO didn't offer numbers, but said a few times that the profit margin was "healthy" and implied the drug would be going a long way to make them profitable  in 2017.  One analyst kept hammering on generic competition and Adams said many had tried to get a generic through the FDA and failed because of the complexity of it; but even if someone succeeded, they were happy with their position.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities